Carotid Artery Approach as an Alternative to Femoral access for Balloon Dilation of Aortic Valve Stenosis in Neonates and Infants

2003 ◽  
Vol 4 (4) ◽  
pp. 146-149 ◽  
Author(s):  
M. Gasparella ◽  
O. Milanesi ◽  
R. Biffanti ◽  
A. Cerruti ◽  
M. Sabatti ◽  
...  
1990 ◽  
Vol 15 (7) ◽  
pp. 1633-1636 ◽  
Author(s):  
Donald R. Fischer ◽  
Jose A. Edgui ◽  
Sang C. Park ◽  
RalphD. Siewers ◽  
Pedro J. del Nido

2014 ◽  
Vol 36 (3) ◽  
pp. 616-624 ◽  
Author(s):  
Sergej M. Prijic ◽  
Vladislav A. Vukomanovic ◽  
Mila S. Stajevic ◽  
Bojko B. Bjelakovic ◽  
Marija D. Zdravkovic ◽  
...  

2009 ◽  
Vol 26 (7) ◽  
pp. 823-831 ◽  
Author(s):  
Francesco Antonini-Canterin ◽  
Monica RoÅŸca ◽  
Carmen C. Beladan ◽  
Bogdan A. Popescu ◽  
Rita Piazza ◽  
...  

Author(s):  
Riccardo Cocchieri ◽  
Ezra Y. Koh ◽  
Laurens W. Wollersheim ◽  
Paola G. Meregalli ◽  
Abdenasser Bardai ◽  
...  

Objective Transaortic aortic valve implantation (TAo-AVI) through the ascending aorta is a novel technique and is used as an alternative in patients with poor femoral access. Although early results have been promising, no midterm data have been published yet. To determine whether this approach is an acceptable treatment option, we analyzed the first 100 cases performed at our institution with a follow-up to 3 years. Methods Between July 2011 and January 2015, a total of 100 patients with high-risk or inoperable aortic valve stenosis were treated with TAo-AVI. Preoperative patient data were collected and analyzed retrospectively. All surviving patients were seen for clinical and echocardiographic examination for follow-up. Results Median follow-up was 15 months. Device success was accomplished in 94 patients (94%). There were no access site complications. The 30-day mortality rate was 9%. Stroke occurred in a total of six patients (6%). Survival at 1-, 2-, and 3 years was 75%, 62%, and 58%, respectively. Conclusions Our results show that TAo-AVI is a promising alternative to transapical implantation for treating severe inoperable aortic valve stenosis.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Chadi Aludaat ◽  
Alexandre Canville ◽  
Quentin Landolff ◽  
Matthieu Godin ◽  
Fabrice Bauer ◽  
...  

Abstract Background The ACURATE neo™ transcatheter heart valve (Boston Scientific, Marlborough, Massachusetts) is predominantly implanted via femoral access. Transcarotid use of this prothesis has never been reported. Case presentation We present the case of an 89-year-old woman referred to us for a transcatheter aortic valve replacement (TAVR). After apparatus imaging of the aortic annulus and the peripheral vascular pathway, the heart team was confronted with a triple challenge: (i) The preferable choice of a self-expanding valve because of a small aortic annulus in an obese woman. (ii) Gaining favorable access to the coronary ostia, considering multiple recent coronary stenting. (iii) Utilizing an alternative arterial access because of iliac and femoral severely calcified stenosis. Implanting the ACURATE neo™ transcatheter heart valve (THV) via carotidal access allowed us to overcome these challenges. The procedure was performed successfully without any short-term complications. Conclusion We report the first case of implantation of an ACURATE neo™ transcatheter heart valve (Boston Scientific, Marlborough, Massachusetts) via the right common carotid artery.


1993 ◽  
Vol 28 (2) ◽  
pp. 134-136 ◽  
Author(s):  
Martin P. O'Laughlin ◽  
Michael C. Slack ◽  
Ronald Grifka ◽  
Charles E. Mullins

2021 ◽  
Vol 13 (4) ◽  
pp. 329-330
Author(s):  
G. Carles ◽  
M. Lenoir ◽  
E. Aries ◽  
F. El Louali ◽  
O. Raisky ◽  
...  

1991 ◽  
Vol 22 (2) ◽  
pp. 89-92
Author(s):  
Achi Ludomirsky ◽  
Martin P. O'Laughlin ◽  
Michael R. Nihill ◽  
Charles E. Mullins

Sign in / Sign up

Export Citation Format

Share Document